The protective role of DPP4 inhibitors in atherosclerosis

Diabetes is a chronic non-communicable disease whose incidence continues to grow rapidly, and it is one of the most serious and critical public health problems. Diabetes complications, especially atherosclerosis-related chronic vascular complications, are a serious threat to human life and health. G...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of pharmacology 2020-05, Vol.875, p.173037-173037, Article 173037
Hauptverfasser: Liu, Hengdao, Guo, Lingli, Xing, Junhui, Li, Peicheng, Sang, Haiqiang, Hu, Xiaofang, Du, Yunpeng, Zhao, Liangping, Song, Ruipeng, Gu, Heping
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 173037
container_issue
container_start_page 173037
container_title European journal of pharmacology
container_volume 875
creator Liu, Hengdao
Guo, Lingli
Xing, Junhui
Li, Peicheng
Sang, Haiqiang
Hu, Xiaofang
Du, Yunpeng
Zhao, Liangping
Song, Ruipeng
Gu, Heping
description Diabetes is a chronic non-communicable disease whose incidence continues to grow rapidly, and it is one of the most serious and critical public health problems. Diabetes complications, especially atherosclerosis-related chronic vascular complications, are a serious threat to human life and health. Growing evidence suggests that dipeptidyl peptidase 4 (DPP4) inhibitors, beyond their role in improving glycemic control, are helpful in ameliorating endothelial dysfunction in humans and animal models of T2DM. In fact, DPP4 inhibitors have been shown by successive studies to play a protective effect against vascular complications. On one hand, in addition to their hypoglycemic effects, DPP4 inhibitors participate in the control of atherosclerotic risk factors by regulating blood lipids and lowering blood pressure. On the other hand, DPP4 inhibitors exert anti-atherosclerotic effects directly through multiple mechanisms, including improving endothelial cell dysfunction, increasing circulating endothelial progenitor cell (EPCs) levels, regulating mononuclear macrophages and smooth muscle cells, inhibiting inflammation and oxidative stress and improving plaque instability. Herein, we review the beneficial roles of DPP4 inhibitors in atherosclerosis as detailed.
doi_str_mv 10.1016/j.ejphar.2020.173037
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2365205287</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0014299920301291</els_id><sourcerecordid>2365205287</sourcerecordid><originalsourceid>FETCH-LOGICAL-c362t-4aab7e4441ca0da59aead4ca77009180e293fa5abdefeb20c031491045b660023</originalsourceid><addsrcrecordid>eNp9kE1PwzAMhiMEYmPwDxDqkUuH89UsFyTEtzSJHcY5SlNXzdStI-km8e_J1MGRi21Zr_3aDyHXFKYUaHG3muJq29gwZcBSS3Hg6oSM6UzpHBRlp2QMQEXOtNYjchHjCgCkZvKcjDgDrQpZjIleNphtQ9ej6_0es9C1mHV19rRYiMxvGl_6vgsxlZntGwxddO0h-nhJzmrbRrw65gn5fHlePr7l84_X98eHee54wfpcWFsqFEJQZ6GyUlu0lXBWKQBNZ4BM89pKW1ZYY8nAAadCUxCyLAoAxifkdtibrvzaYezN2keHbWs32O2iYbyQDCSbqSQVg9SlC2PA2myDX9vwbSiYAzSzMgM0c4BmBmhp7ObosCvXWP0N_VJKgvtBgOnPvcdgovO4cVj5kLiZqvP_O_wAbrZ-Uw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2365205287</pqid></control><display><type>article</type><title>The protective role of DPP4 inhibitors in atherosclerosis</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Liu, Hengdao ; Guo, Lingli ; Xing, Junhui ; Li, Peicheng ; Sang, Haiqiang ; Hu, Xiaofang ; Du, Yunpeng ; Zhao, Liangping ; Song, Ruipeng ; Gu, Heping</creator><creatorcontrib>Liu, Hengdao ; Guo, Lingli ; Xing, Junhui ; Li, Peicheng ; Sang, Haiqiang ; Hu, Xiaofang ; Du, Yunpeng ; Zhao, Liangping ; Song, Ruipeng ; Gu, Heping</creatorcontrib><description>Diabetes is a chronic non-communicable disease whose incidence continues to grow rapidly, and it is one of the most serious and critical public health problems. Diabetes complications, especially atherosclerosis-related chronic vascular complications, are a serious threat to human life and health. Growing evidence suggests that dipeptidyl peptidase 4 (DPP4) inhibitors, beyond their role in improving glycemic control, are helpful in ameliorating endothelial dysfunction in humans and animal models of T2DM. In fact, DPP4 inhibitors have been shown by successive studies to play a protective effect against vascular complications. On one hand, in addition to their hypoglycemic effects, DPP4 inhibitors participate in the control of atherosclerotic risk factors by regulating blood lipids and lowering blood pressure. On the other hand, DPP4 inhibitors exert anti-atherosclerotic effects directly through multiple mechanisms, including improving endothelial cell dysfunction, increasing circulating endothelial progenitor cell (EPCs) levels, regulating mononuclear macrophages and smooth muscle cells, inhibiting inflammation and oxidative stress and improving plaque instability. Herein, we review the beneficial roles of DPP4 inhibitors in atherosclerosis as detailed.</description><identifier>ISSN: 0014-2999</identifier><identifier>EISSN: 1879-0712</identifier><identifier>DOI: 10.1016/j.ejphar.2020.173037</identifier><identifier>PMID: 32097656</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Animals ; Atherosclerosis - blood ; Atherosclerosis - etiology ; Atherosclerosis - pathology ; Atherosclerosis - prevention &amp; control ; Blood Pressure - drug effects ; Diabetes Mellitus, Type 2 - blood ; Diabetes Mellitus, Type 2 - complications ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetic chronic vascular complications ; Dipeptidyl Peptidase 4 - blood ; Dipeptidyl Peptidase 4 - metabolism ; Dipeptidyl-Peptidase IV Inhibitors - pharmacology ; Dipeptidyl-Peptidase IV Inhibitors - therapeutic use ; Disease Models, Animal ; DPP4 inhibitors ; Endothelial Cells - drug effects ; Endothelial Cells - pathology ; Endothelium, Vascular - cytology ; Endothelium, Vascular - drug effects ; Endothelium, Vascular - pathology ; Humans ; Lipid Metabolism - drug effects ; Lipids - blood ; Oxidative Stress - drug effects ; Protective role ; Risk Factors</subject><ispartof>European journal of pharmacology, 2020-05, Vol.875, p.173037-173037, Article 173037</ispartof><rights>2020</rights><rights>Copyright © 2020. Published by Elsevier B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c362t-4aab7e4441ca0da59aead4ca77009180e293fa5abdefeb20c031491045b660023</citedby><cites>FETCH-LOGICAL-c362t-4aab7e4441ca0da59aead4ca77009180e293fa5abdefeb20c031491045b660023</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0014299920301291$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32097656$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Liu, Hengdao</creatorcontrib><creatorcontrib>Guo, Lingli</creatorcontrib><creatorcontrib>Xing, Junhui</creatorcontrib><creatorcontrib>Li, Peicheng</creatorcontrib><creatorcontrib>Sang, Haiqiang</creatorcontrib><creatorcontrib>Hu, Xiaofang</creatorcontrib><creatorcontrib>Du, Yunpeng</creatorcontrib><creatorcontrib>Zhao, Liangping</creatorcontrib><creatorcontrib>Song, Ruipeng</creatorcontrib><creatorcontrib>Gu, Heping</creatorcontrib><title>The protective role of DPP4 inhibitors in atherosclerosis</title><title>European journal of pharmacology</title><addtitle>Eur J Pharmacol</addtitle><description>Diabetes is a chronic non-communicable disease whose incidence continues to grow rapidly, and it is one of the most serious and critical public health problems. Diabetes complications, especially atherosclerosis-related chronic vascular complications, are a serious threat to human life and health. Growing evidence suggests that dipeptidyl peptidase 4 (DPP4) inhibitors, beyond their role in improving glycemic control, are helpful in ameliorating endothelial dysfunction in humans and animal models of T2DM. In fact, DPP4 inhibitors have been shown by successive studies to play a protective effect against vascular complications. On one hand, in addition to their hypoglycemic effects, DPP4 inhibitors participate in the control of atherosclerotic risk factors by regulating blood lipids and lowering blood pressure. On the other hand, DPP4 inhibitors exert anti-atherosclerotic effects directly through multiple mechanisms, including improving endothelial cell dysfunction, increasing circulating endothelial progenitor cell (EPCs) levels, regulating mononuclear macrophages and smooth muscle cells, inhibiting inflammation and oxidative stress and improving plaque instability. Herein, we review the beneficial roles of DPP4 inhibitors in atherosclerosis as detailed.</description><subject>Animals</subject><subject>Atherosclerosis - blood</subject><subject>Atherosclerosis - etiology</subject><subject>Atherosclerosis - pathology</subject><subject>Atherosclerosis - prevention &amp; control</subject><subject>Blood Pressure - drug effects</subject><subject>Diabetes Mellitus, Type 2 - blood</subject><subject>Diabetes Mellitus, Type 2 - complications</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Diabetic chronic vascular complications</subject><subject>Dipeptidyl Peptidase 4 - blood</subject><subject>Dipeptidyl Peptidase 4 - metabolism</subject><subject>Dipeptidyl-Peptidase IV Inhibitors - pharmacology</subject><subject>Dipeptidyl-Peptidase IV Inhibitors - therapeutic use</subject><subject>Disease Models, Animal</subject><subject>DPP4 inhibitors</subject><subject>Endothelial Cells - drug effects</subject><subject>Endothelial Cells - pathology</subject><subject>Endothelium, Vascular - cytology</subject><subject>Endothelium, Vascular - drug effects</subject><subject>Endothelium, Vascular - pathology</subject><subject>Humans</subject><subject>Lipid Metabolism - drug effects</subject><subject>Lipids - blood</subject><subject>Oxidative Stress - drug effects</subject><subject>Protective role</subject><subject>Risk Factors</subject><issn>0014-2999</issn><issn>1879-0712</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1PwzAMhiMEYmPwDxDqkUuH89UsFyTEtzSJHcY5SlNXzdStI-km8e_J1MGRi21Zr_3aDyHXFKYUaHG3muJq29gwZcBSS3Hg6oSM6UzpHBRlp2QMQEXOtNYjchHjCgCkZvKcjDgDrQpZjIleNphtQ9ej6_0es9C1mHV19rRYiMxvGl_6vgsxlZntGwxddO0h-nhJzmrbRrw65gn5fHlePr7l84_X98eHee54wfpcWFsqFEJQZ6GyUlu0lXBWKQBNZ4BM89pKW1ZYY8nAAadCUxCyLAoAxifkdtibrvzaYezN2keHbWs32O2iYbyQDCSbqSQVg9SlC2PA2myDX9vwbSiYAzSzMgM0c4BmBmhp7ObosCvXWP0N_VJKgvtBgOnPvcdgovO4cVj5kLiZqvP_O_wAbrZ-Uw</recordid><startdate>20200515</startdate><enddate>20200515</enddate><creator>Liu, Hengdao</creator><creator>Guo, Lingli</creator><creator>Xing, Junhui</creator><creator>Li, Peicheng</creator><creator>Sang, Haiqiang</creator><creator>Hu, Xiaofang</creator><creator>Du, Yunpeng</creator><creator>Zhao, Liangping</creator><creator>Song, Ruipeng</creator><creator>Gu, Heping</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20200515</creationdate><title>The protective role of DPP4 inhibitors in atherosclerosis</title><author>Liu, Hengdao ; Guo, Lingli ; Xing, Junhui ; Li, Peicheng ; Sang, Haiqiang ; Hu, Xiaofang ; Du, Yunpeng ; Zhao, Liangping ; Song, Ruipeng ; Gu, Heping</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c362t-4aab7e4441ca0da59aead4ca77009180e293fa5abdefeb20c031491045b660023</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Animals</topic><topic>Atherosclerosis - blood</topic><topic>Atherosclerosis - etiology</topic><topic>Atherosclerosis - pathology</topic><topic>Atherosclerosis - prevention &amp; control</topic><topic>Blood Pressure - drug effects</topic><topic>Diabetes Mellitus, Type 2 - blood</topic><topic>Diabetes Mellitus, Type 2 - complications</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Diabetic chronic vascular complications</topic><topic>Dipeptidyl Peptidase 4 - blood</topic><topic>Dipeptidyl Peptidase 4 - metabolism</topic><topic>Dipeptidyl-Peptidase IV Inhibitors - pharmacology</topic><topic>Dipeptidyl-Peptidase IV Inhibitors - therapeutic use</topic><topic>Disease Models, Animal</topic><topic>DPP4 inhibitors</topic><topic>Endothelial Cells - drug effects</topic><topic>Endothelial Cells - pathology</topic><topic>Endothelium, Vascular - cytology</topic><topic>Endothelium, Vascular - drug effects</topic><topic>Endothelium, Vascular - pathology</topic><topic>Humans</topic><topic>Lipid Metabolism - drug effects</topic><topic>Lipids - blood</topic><topic>Oxidative Stress - drug effects</topic><topic>Protective role</topic><topic>Risk Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Liu, Hengdao</creatorcontrib><creatorcontrib>Guo, Lingli</creatorcontrib><creatorcontrib>Xing, Junhui</creatorcontrib><creatorcontrib>Li, Peicheng</creatorcontrib><creatorcontrib>Sang, Haiqiang</creatorcontrib><creatorcontrib>Hu, Xiaofang</creatorcontrib><creatorcontrib>Du, Yunpeng</creatorcontrib><creatorcontrib>Zhao, Liangping</creatorcontrib><creatorcontrib>Song, Ruipeng</creatorcontrib><creatorcontrib>Gu, Heping</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Liu, Hengdao</au><au>Guo, Lingli</au><au>Xing, Junhui</au><au>Li, Peicheng</au><au>Sang, Haiqiang</au><au>Hu, Xiaofang</au><au>Du, Yunpeng</au><au>Zhao, Liangping</au><au>Song, Ruipeng</au><au>Gu, Heping</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The protective role of DPP4 inhibitors in atherosclerosis</atitle><jtitle>European journal of pharmacology</jtitle><addtitle>Eur J Pharmacol</addtitle><date>2020-05-15</date><risdate>2020</risdate><volume>875</volume><spage>173037</spage><epage>173037</epage><pages>173037-173037</pages><artnum>173037</artnum><issn>0014-2999</issn><eissn>1879-0712</eissn><abstract>Diabetes is a chronic non-communicable disease whose incidence continues to grow rapidly, and it is one of the most serious and critical public health problems. Diabetes complications, especially atherosclerosis-related chronic vascular complications, are a serious threat to human life and health. Growing evidence suggests that dipeptidyl peptidase 4 (DPP4) inhibitors, beyond their role in improving glycemic control, are helpful in ameliorating endothelial dysfunction in humans and animal models of T2DM. In fact, DPP4 inhibitors have been shown by successive studies to play a protective effect against vascular complications. On one hand, in addition to their hypoglycemic effects, DPP4 inhibitors participate in the control of atherosclerotic risk factors by regulating blood lipids and lowering blood pressure. On the other hand, DPP4 inhibitors exert anti-atherosclerotic effects directly through multiple mechanisms, including improving endothelial cell dysfunction, increasing circulating endothelial progenitor cell (EPCs) levels, regulating mononuclear macrophages and smooth muscle cells, inhibiting inflammation and oxidative stress and improving plaque instability. Herein, we review the beneficial roles of DPP4 inhibitors in atherosclerosis as detailed.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>32097656</pmid><doi>10.1016/j.ejphar.2020.173037</doi><tpages>1</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0014-2999
ispartof European journal of pharmacology, 2020-05, Vol.875, p.173037-173037, Article 173037
issn 0014-2999
1879-0712
language eng
recordid cdi_proquest_miscellaneous_2365205287
source MEDLINE; Elsevier ScienceDirect Journals
subjects Animals
Atherosclerosis - blood
Atherosclerosis - etiology
Atherosclerosis - pathology
Atherosclerosis - prevention & control
Blood Pressure - drug effects
Diabetes Mellitus, Type 2 - blood
Diabetes Mellitus, Type 2 - complications
Diabetes Mellitus, Type 2 - drug therapy
Diabetic chronic vascular complications
Dipeptidyl Peptidase 4 - blood
Dipeptidyl Peptidase 4 - metabolism
Dipeptidyl-Peptidase IV Inhibitors - pharmacology
Dipeptidyl-Peptidase IV Inhibitors - therapeutic use
Disease Models, Animal
DPP4 inhibitors
Endothelial Cells - drug effects
Endothelial Cells - pathology
Endothelium, Vascular - cytology
Endothelium, Vascular - drug effects
Endothelium, Vascular - pathology
Humans
Lipid Metabolism - drug effects
Lipids - blood
Oxidative Stress - drug effects
Protective role
Risk Factors
title The protective role of DPP4 inhibitors in atherosclerosis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-20T04%3A58%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20protective%20role%20of%20DPP4%20inhibitors%20in%20atherosclerosis&rft.jtitle=European%20journal%20of%20pharmacology&rft.au=Liu,%20Hengdao&rft.date=2020-05-15&rft.volume=875&rft.spage=173037&rft.epage=173037&rft.pages=173037-173037&rft.artnum=173037&rft.issn=0014-2999&rft.eissn=1879-0712&rft_id=info:doi/10.1016/j.ejphar.2020.173037&rft_dat=%3Cproquest_cross%3E2365205287%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2365205287&rft_id=info:pmid/32097656&rft_els_id=S0014299920301291&rfr_iscdi=true